Literature DB >> 11082393

Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction.

K Pethig1, B Heublein, I Kutschka, A Haverich.   

Abstract

BACKGROUND: Response to immunologic and nonimmunologic injury has been reported to initiate the development of cardiac allograft vasculopathy (CAVD). Although histopathologic examinations reveal signs of focal inflammation, little is known about the systemic inflammatory response in this accelerated coronary syndrome. METHODS AND
RESULTS: Therefore, we investigated high-sensitive C-reactive protein (CRP) in a large cohort of heart transplant (HTX) recipients (n=102, 90 male, mean age 45.2+/-11.5 years, 6.1+/-3.3 years after HTX) in correlation with a progression of luminal obstruction as assessed by serial coronary angiography (defined as an increase of focal stenosis >/=30% or detection of a new lesion) after a mean interval of 1.8+/-1.0 years. Patients with signs of an acute rejection or infection were excluded. In the entire group, CRP levels ranged from 0.2 to 12.7 mg/L (mean 2.6+/-2.7 mg/L). Patients with progressive CAVD (n=35) presented with significantly higher levels of CRP (4.1+/-3.3 mg/L) than did those with a nonprogressive course (n=67) (1.8+/-1.9 mg/L, P:=0.001). These observations were independent of the initial indication for HTX (atherosclerotic disorder versus cardiomyopathy, P:=0.18) and the severity of CAVD at baseline examination (P:=0.12).
CONCLUSIONS: Progressive cardiac allograft vasculopathy is accompanied by a systemic inflammatory reaction, which gives further insight into the pathogenesis of this coronary syndrome and may well serve as an indicator for patients at risk.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082393     DOI: 10.1161/01.cir.102.suppl_3.iii-233

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

Review 1.  Pharmacotherapy of hyperlipidemia in pediatric heart transplant recipients: current practice and future directions.

Authors:  Clifford Chin; Daniel Bernstein
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Multicenter assessment of coronary allograft vasculopathy by intravascular ultrasound-derived analysis of plaque composition.

Authors:  Giovanna Sarno; Amir Lerman; Jang-Ho Bae; Christoph Schukro; Dietmar Glogar; Pauliina M Margolis; Marc Goethals; Sofie Verstreken; Jozef Bartunek; Andreas Koenig; William Wijns; Marc Vanderheyden
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-02

3.  Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients.

Authors:  Eugenia Raichlin; Joseph P McConnell; Jang-Ho Bae; Walter K Kremers; Amir Lerman; Robert P Frantz
Journal:  Transplantation       Date:  2008-04-15       Impact factor: 4.939

4.  Gene Expression Signatures of Peripheral Blood Mononuclear Cells during the Early Post-Transplant Period in Patients Developing Cardiac Allograft Vasculopathy.

Authors:  Khurram Shahzad; Martin Cadeiras; Sarfaraz Memon; Barry Zeeberg; Tod Klingler; Anshu Sinha; Esteban G Tabak; Sreevalsa Unniachan; Mario C Deng
Journal:  J Transplant       Date:  2010-12-28

5.  Risk factors of cardiac allograft vasculopathy.

Authors:  Bożena Szyguła-Jurkiewicz; Wioletta Szczurek; Mariusz Gąsior; Marian Zembala
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-12-30

6.  Medium-term outcome of recipients of marginal donor hearts selected with new stress-echocardiographic techniques over standard criteria.

Authors:  Tonino Bombardini; Giorgio Arpesella; Massimo Maccherini; Francesco Procaccio; Luciano Potena; Sonia Bernazzali; Ornella Leone; Eugenio Picano
Journal:  Cardiovasc Ultrasound       Date:  2014-06-16       Impact factor: 2.062

7.  Ischemic cardiomyopathy is associated with coronary plaque progression and higher event rate in patients after cardiac transplantation.

Authors:  Raviteja R Guddeti; Yoshiki Matsuo; Yasushi Matsuzawa; Tatsuo Aoki; Ryan J Lennon; Lilach O Lerman; Sudhir S Kushwaha; Amir Lerman
Journal:  J Am Heart Assoc       Date:  2014-08-05       Impact factor: 5.501

8.  Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients.

Authors:  Carlos A Labarrere; John R Woods; James W Hardin; Beate R Jaeger; Marian Zembala; Mario C Deng; Ghassan S Kassab
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

9.  Interleukin 21 (IL-21) regulates chronic allograft vasculopathy (CAV) in murine heart allograft rejection.

Authors:  Mithun Khattar; Caitlin E Baum; Paul Schroder; Joshua D Breidenbach; Steven T Haller; Wenhao Chen; Stanislaw Stepkowski
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.